Samsung Biologics Publishes PolyPeptide Offer Prospectus; Sets Tender Period

Samsung Biologics said its Swiss unit, Samsung Peptide AG, has published the tender offer prospectus to acquire all publicly held shares of PolyPeptide Group AG. The update is a procedural step toward completion, with potential implications for deal timing and shareholder acceptance but no disclosed financial terms in the news text.